Chemoinformaics analysis of BUTYL-VALERIANATE
| Molecular Weight | 158.241 | nRot | 6 |
| Heavy Atom Molecular Weight | 140.097 | nRig | 1 |
| Exact Molecular Weight | 158.131 | nRing | 0 |
| Solubility: LogS | -3.097 | nHRing | 0 |
| Solubility: LogP | 3.293 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 29 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 28.6363 |
| nHD | 0 | BPOL | 20.6617 |
| QED | 0.438 |
| Synth | 1.662 |
| Natural Product Likeliness | 0.029 |
| NR-PPAR-gamma | 0.017 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.169 |
| Pgp-sub | 0.008 |
| HIA | 0.002 |
| CACO-2 | -4.34 |
| MDCK | 0.0000305 |
| BBB | 0.933 |
| PPB | 0.836767 |
| VDSS | 0.555 |
| FU | 0.243057 |
| CYP1A2-inh | 0.984 |
| CYP1A2-sub | 0.662 |
| CYP2c19-inh | 0.772 |
| CYP2c19-sub | 0.547 |
| CYP2c9-inh | 0.497 |
| CYP2c9-sub | 0.702 |
| CYP2d6-inh | 0.047 |
| CYP2d6-sub | 0.139 |
| CYP3a4-inh | 0.101 |
| CYP3a4-sub | 0.182 |
| CL | 11.853 |
| T12 | 0.818 |
| hERG | 0.091 |
| Ames | 0.006 |
| ROA | 0.072 |
| SkinSen | 0.814 |
| Carcinogencity | 0.275 |
| EI | 0.983 |
| Respiratory | 0.219 |
| NR-Aromatase | 0.016 |
| Antiviral | No |
| Prediction | 0.94998 |